Circulating Tumour DNA (CtDNA) Clearance Predicts Better Osimertinib Treatment Outcomes (PLASMA Study)
16609
post-template-default,single,single-post,postid-16609,single-format-standard,bridge-core-1.0.4,ajax_fade,page_not_loaded,,qode-content-sidebar-responsive,qode-child-theme-ver-1.0.0,qode-theme-ver-18.0.9,qode-theme-bridge,qode_header_in_grid,bridge-child,wpb-js-composer js-comp-ver-5.7,vc_responsive
 

Circulating Tumour DNA (CtDNA) Clearance Predicts Better Osimertinib Treatment Outcomes (PLASMA Study)

Home > Blogs  > Circulating Tumour DNA (CtDNA) Clearance Predicts Better Osimertinib Treatment Outcomes (PLASMA Study)

31 Oct Circulating Tumour DNA (CtDNA) Clearance Predicts Better Osimertinib Treatment Outcomes (PLASMA Study)

Posted at 05:30h in Blogs by

In this phase 2 study, patients with advanced NSCLC harbouring sensitizing EGFR and T790M mutations in plasma at progression from ≥one 1G/2G TKI were treated with 80 mg of Osimertinib daily until progression. During the treatment, ctDNA clearance at Cycle 3 (C3) showed improved PFS (median 15.2 months vs. 6.0 months, HR 0.37, 95% CI 0.23–0.60) and OS (median 34.0 months vs. 17.2 months, HR 0.42, 95% CI 0.24–0.72) compared to patients who did not clear ctDNA at C3. The ctDNA baseline load as well as dynamics can be prognostic, and blood testing for T790M can be used as a surrogate marker to guide Osimertinib use. (Ref: Ang YLE, et al. Cancers. October 16, 2023)

#oncologyresearch #clinicalresearch #clinicaldevelopment

No Comments

Sorry, the comment form is closed at this time.